Table 2.
Disease features: tumour site
| Reference | Number of patients | Oropharynx | Larynx | Hypopharynx | Oral cavity | Nasopharynx | Other | |
|---|---|---|---|---|---|---|---|---|
| Total | p16/HPV-positive | |||||||
| [18] | 62 | 14 (22%) | ns | 10 (16%) | 12 (20%) | 3 (5%) | 14 (22%) | 9 (15%) |
| [19] | 26 | 12 (46%) | ns | 9 (35%) | 2 (8%) | 0 | 3 (11%) | 0 |
| [20] | 122 | 122 (100%) | 32 (26%) | 0 | 0 | 0 | 0 | 0 |
| [21] | 51 | 20 (39%) | ns | 0 | 21 (41%) | 0 | 10 (20%) | 0 |
| [22] | 70 | 70 (100%) | 13 (19%) | 0 | 0 | 0 | 0 | 0 |
| [23] | 82 | 13 (16%) | ns | 0 | 6 (7%) | 0 | 63 (77%) | 0 |
| [24] | 88 | 58 (66%) | ns | 15 (17%) | 0 | 1 (1%) | 7 (8%) | 7 (8%) |
| [25] | 70 | 25 (36%) | ns | 0 | 36 (51%) | 0 | 9 (13%) | 0 |
| [26] | 78 | 47 (61%) | ns | 3 (4%) | 19 (24%) | 5 (6%) | 0 | 4 (5%) |
| [27] | 108 | 28 (26%) | ns | 29 (27%) | 34 (31%) | 17 (16%) | 0 | 0 |
| [28] | 75 | 56 (75%) | ns | 11 (15%) | 5 (6%) | 3 (4%) | 0 | 0 |
| [29] | 214 | 135 (63%) | 123 (57%) | 40 (19%) | 0 | 11 (5%) | 0 | 28: (13%) |
| [30] | 35 | 9 (26%) | ns | 11 (31%) | 12 (34%) | 3 (9%) | 0 | 0 |
| [31] | 69 | 41 (59%) | ns | 20 (30%) | 5 (7%) | 3 (4%) | 0 | 0 |
| [32] | 72 | 47 (66%) | ns | 16 (22%) | 6 (8%) | 3 (4%) | 0 | 0 |
| [34] | 85 | 0 | ns | 35 (41%) | 50 (59%) | 0 | 0 | 0 |
| [35] | 47 | 21 (45%) | ns | 7 (15%) | 4 (8%) | 2 (4%) | 13 (28%) | 0 |
| [36] | 86 | 45 (52%) | ns | 0 | 41 (48%) | 0 | 0 | 0 |
| [37] | 81 | 0 | ns | 57 (70%) | 24 (30%) | 0 | 0 | 0 |
| [38] | 287 | 129 (45%) | ns | 44 (15%) | 55 (19%) | 29 (10%) | 30 (11%) | 0 |
| [39] | 100 | 100 (100%) | 14 (14%) | 0 | 0 | 0 | 0 | 0 |
| [40] | 74 | 58 (78%) | 25 (34%) | 9 (12%) | 7 (10%) | 0 | 0 | 0 |
| [42] | 125 | 69 (56%) | 37 (30%) | 21 (17%) | 11 (9%) | 8 (6%) | 8 (6%) | 8 (6%) |
| [43] | 40 | 0 | 0 | 0 | 0 | 0 | 40 (100%) | 0 |
| [44] | 76 | 31 (41%) | 3 (4%) | 8 (10%) | 27 (36%) | 10 (13%) | 0 | 0 |
ns not stated